Literature DB >> 12651209

Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression.

B Porsin1, J-L Formento, E Filipski, M-C Etienne, M Francoual, N Renée, N Magné, F Lévi, G Milano.   

Abstract

Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme of 5-fluorouracil (FU) catabolism. The relevance of the measurement of DPD activity for identifying DPD-deficient patients is lessened by circadian variability in DPD activity. Our purpose was to determine whether or not DPD mRNA is sustained by a circadian rhythm. Synchronised mice (male B6D2F1) were sacrificed at 3, 7, 11, 15, 19 or 23 Hours After Light Onset (HALO; eight mice per time-point). Liver DPD activity was determined by a radio-enzymatic assay and liver DPD expression by a reverse transcriptase-polymerase chain reaction (RT-PCR) enzyme-linked immunosorbent assay (ELISA) method. Mice synchronisation was controlled by leucocyte and neutrophil counts. Individual DPD activity ranged from 555 to 1575 pmol/min/mg prot; mean DPD activity was highest at 3 HALO (mean+/-standard error of the mean (S.E.M.); 1105+/-70) and lowest at 15 HALO (889+/-71). Individual liver DPD expression varied from 761 to 3481 units (DPD/beta actin ratio); the mean was lowest at 3 HALO (1406+/-112) and highest at 15 HALO (2067+/-214). Cosinor analysis indicated that respective double amplitudes of DPD activity and expression were 21 and 30% of the 24-h mean. The acrophases for activity and expression were 6:40 and 14:10 HALO, respectively, meaning that maximum activity occurred 16 h after the maximum observed expression. These results, revealing the existence of a circadian rhythm in DPD expression, should stimulate further studies to enhance our understanding of the molecular mechanisms involved in the circadian regulation of the DPD enzyme.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12651209     DOI: 10.1016/s0959-8049(02)00598-1

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Analysis of pyrimidine catabolism in Drosophila melanogaster using epistatic interactions with mutations of pyrimidine biosynthesis and beta-alanine metabolism.

Authors:  John M Rawls
Journal:  Genetics       Date:  2005-12-15       Impact factor: 4.562

2.  Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.

Authors:  Jin Ho Baek; Jong Gwang Kim; Shi Nae Kim; Dong Hwan Kim; Sang Kyun Sohn; Young Jun Hong; Kyu Bo Lee
Journal:  Korean J Intern Med       Date:  2006-03       Impact factor: 2.884

3.  Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.

Authors:  Hao Jiang; Jing Lu; Jiang Ji
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

4.  A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery.

Authors:  Annabelle Ballesta; Sandrine Dulong; Chadi Abbara; Boris Cohen; Alper Okyar; Jean Clairambault; Francis Levi
Journal:  PLoS Comput Biol       Date:  2011-09-08       Impact factor: 4.475

Review 5.  Molecular Aspects of Circadian Pharmacology and Relevance for Cancer Chronotherapy.

Authors:  Narin Ozturk; Dilek Ozturk; Ibrahim Halil Kavakli; Alper Okyar
Journal:  Int J Mol Sci       Date:  2017-10-17       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.